Reata Pharmaceuticals, Inc. Class A

Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.

RETA's P/E is negative making this valuation measure meaningless.

Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

RETA's P/CF is negative making the measure meaningless.

Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.

RETA's ratio is negative making this valuation measure meaningless.

Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

Ratio not available.

Premium. A higher price-to-book ratio makes a stock less attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

RETA is trading at a significant premium to its peers.

Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

However, RETA is expected to significantly trail its peers on the basis of its earnings growth rate.

Premium. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

RETA is trading at a significant premium to its subsector.

Lower. A sales growth rate that trails the subsector implies that a company is losing market share.

RETA significantly trails its peers on the basis of sales growth.